alexa Attitudes toward molecular testing for personalized cancer therapy.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Yusuf RA, Rogith D, Hovick SR, Peterson SK, BurtonChase AM, , Yusuf RA, Rogith D, Hovick SR, Peterson SK, BurtonChase AM,

Abstract Share this page

Abstract BACKGROUND: This study assessed attitudes of breast cancer patients toward molecular testing for personalized therapy and research. METHODS: A questionnaire was given to female breast cancer patients presenting to a cancer center. Associations between demographic and clinical variables and attitudes toward molecular testing were evaluated. RESULTS: Three hundred eight patients were approached, and 100 completed the questionnaire (a 32\% response rate). Most participants were willing to undergo molecular testing to assist in the selection of approved drugs (81\%) and experimental therapy (59\%) if testing was covered by insurance. Most participants were white (71\%). Even if testing was financially covered, nonwhite participants were less willing to undergo molecular testing for the selection of approved drugs (54\% of nonwhites vs 90\% of whites, odds ratio [OR] = 0.13, P = .0004) or experimental drugs (35\% vs 68\%, OR = 0.26, P = .0072). Most participants (75\%) were willing to undergo a biopsy to guide therapy, and 46\% were willing to undergo research biopsies. Nonwhite participants were less willing to undergo research biopsies (17\% vs 55\%, OR = 0.17, P = .0033). Most participants wanted to be informed when research results had implications for treatment (91\%), new cancer risk (90\%), and other preventable/treatable diseases (87\%). CONCLUSIONS: Most patients were willing to undergo molecular testing and minimally invasive procedures to guide approved or experimental therapy. There were significant differences in attitudes toward molecular testing between racial groups; nonwhites were less willing to undergo testing even if the results would guide their own therapy. Novel approaches are needed to prevent disparities in the delivery of genomically informed care and to increase minority participation in biomarker-driven trials. Cancer 2015;121:243-50. © 2014 American Cancer Society. © 2014 American Cancer Society.
This article was published in Cancer and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords